Business Context and Reporting Period
Company: American Vanguard Corp (AMVAC Chemical Corporation, a subsidiary)
Filing Date: November 27, 2006
Event: Completion of acquisition of the global Terbufos insecticide product line and Lock 'N Load closed delivery system from BASF Aktiengesellschaft.
Key Financial Metrics
- Acquisition Price: Approximately $42.1 million (subject to post-closing inventory adjustment).
- Financing Structure:
- $22.1 million borrowed under revolving credit facility.
- $20 million new term loan (Delayed Draw Loan).
- Total Credit Facility: $97 million fully-secured facility ($65 million revolving line; $32 million term loans).
- Debt Maturity: Revolving line and Initial Term Loan mature October 7, 2009; Delayed Draw Loan matures January 31, 2007.
- Interest Terms: Prime rate or fixed rate (LIBOR plus margins) based on debt ratios.
Material Changes
The primary material change is the expansion of AMVAC's product portfolio through the acquisition of BASF's Terbufos assets, including active ingredients, trademarks (Counter and Lock 'N Load), manufacturing know-how, and registration rights. This follows a prior acquisition of the Phorate product line from BASF in 2005 for approximately $26.1 million.
Outlook, Risks, and Management Commentary
- Strategic Intent: The acquisition is funded specifically to expand the global insecticide product line.
- Covenants: The company is currently in compliance with all covenants defined in the credit agreement.
- Related Parties: No material relationships exist between the registrant and BASF other than the current transaction, the prior Phorate acquisition, and an existing License and Supply Agreement regarding the herbicide Topramezone.
- Risk Factors: The filing does not explicitly detail new risks beyond standard debt obligations and the requirement to meet debt ratio covenants for interest rate determination.
Investor Verification Checklist
- Verify the final purchase price after the post-closing inventory adjustment.
- Confirm the impact of the new $20 million term loan on the company's leverage ratios and interest coverage.
- Review the specific debt ratio covenants in the credit agreement to assess refinancing risk.
- Assess the integration timeline and regulatory status of the acquired Terbufos product line.